Compare COGT & URBN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | COGT | URBN |
|---|---|---|
| Founded | 2014 | 1970 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Clothing/Shoe/Accessory Stores |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.9B | 5.9B |
| IPO Year | 2018 | 1995 |
| Metric | COGT | URBN |
|---|---|---|
| Price | $34.73 | $72.61 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 15 | 12 |
| Target Price | $36.21 | ★ $86.91 |
| AVG Volume (30 Days) | ★ 1.6M | 1.3M |
| Earning Date | 05-06-2026 | 05-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 18.78 |
| EPS | N/A | ★ 5.06 |
| Revenue | $7,871,000.00 | ★ $6,165,376,000.00 |
| Revenue This Year | N/A | $10.67 |
| Revenue Next Year | $1,733.58 | $7.01 |
| P/E Ratio | ★ N/A | $14.77 |
| Revenue Growth | N/A | ★ 11.07 |
| 52 Week Low | $5.10 | $59.54 |
| 52 Week High | $43.73 | $84.35 |
| Indicator | COGT | URBN |
|---|---|---|
| Relative Strength Index (RSI) | 50.38 | 55.07 |
| Support Level | $33.26 | $72.41 |
| Resistance Level | $37.69 | $73.74 |
| Average True Range (ATR) | 1.34 | 2.83 |
| MACD | 0.24 | 0.42 |
| Stochastic Oscillator | 72.74 | 64.12 |
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.
Founded in 1970, Philadelphia-based Urban Outfitters is a multibrand apparel and home goods retailer that operates nearly 800 stores and e-commerce in the US, which accounts for about 87% of sales, as well as in other regions. Its retail nameplates are Urban Outfitters (22% of fiscal 2026 sales), Free People/Movement (26%), and Anthropologie (42%). Retail accounted for 86% of fiscal 2026 revenue, but Urban Outfitters also sells products through a wholesale operation, owns some restaurants, and operates a fast-growing clothing rental and resale business called Nuuly (9% of sales). Urban Outfitters primarily markets to young adults and offers products across apparel (66% of sales), home goods (16% of sales), accessories (13% of sales), and more.